Endeavor Health Clinical Operations

Endeavor Health Clinical Operations, doing business as Evanston Hospital and subsidiaries, operates as a tax-exempt nonprofit hospital system that receives federal research grants as a prime recipient from the National Institutes of Health and as a sub-recipient on collaborative research grants from NIH component institutes. The organization has no federal contract prime vehicle and does not compete for procurement contracts; its federal footprint consists entirely of research and development funding.

The entity is headquartered at 1301 Central Street in Evanston, Illinois, and operates through a named subsidiary, Northshore University Healthsystem, which carries hospital and research-institute classifications. Endeavor Health's federal work centers on biomedical research in prostate health, maternal-child health outcomes, neurodevelopmental injury, Alzheimer's disease, chronic pain, and clinical implementation science. Recent prime-recipient grants span investigator-initiated projects in benign prostatic hyperplasia pathogenesis, community violence intervention programming, dysmenorrhea and chronic pelvic pain prevention, and pharmacogenetic clinical utility assessment. The organization acts as prime recipient on roughly 65% of its tracked awards and sub-recipient on 35%, reflecting a research portfolio concentrated among academic medical centers and universities that anchor larger, multi-institutional grants.

NIH funding dominates the customer base, accounting for 99% of combined potential value across the award portfolio. The National Institute of Diabetes and Digestive and Kidney Diseases leads by award count (15 prime and sub awards), followed by the National Institute of Child Health and Human Development (12 awards) and the National Cancer Institute and National Institute of Neurological Disorders and Stroke (9 awards each). The Office of the Director carries the largest potential value concentration at $72.9 million across 9 awards, reflecting core facility and research-infrastructure funding. Representative prime-recipient grants include a $529,928 Project Grant from NIDDK awarded May 2026 investigating lipid-rich TREM2+ macrophages in benign prostatic hyperplasia through 2031; a $2 million Project Grant from the Bureau of Justice Assistance awarded October 2024 for hospital-based community violence intervention programming across three Endeavor Health Chicago-area facilities through 2027; and a grant from the National Institute of Neurological Disorders and Stroke awarded September 2024 examining NSAID response variability in dysmenorrhea using a randomized controlled trial of 300 participants to identify chronic pelvic pain risk predictors through 2027.

Sub-recipient engagement spans a diverse network of prime grantees including Northwestern University, the University of Chicago, Washington University, Rutgers University, and the University of Michigan. Endeavor Health contributes specialized research capabilities — clinical site recruitment and screening, placental tissue pathology analysis and processing, kidney functional MRI acquisition and analysis, biostatistical consultation, and perinatal outcomes measurement — that position it as a clinical-research node within larger multi-center studies. Representative sub-awards include participation in Northwestern-led SPORE (Specialized Program of Research Excellence) grants in prostate cancer, co-investigator roles on University of Chicago patient-reported outcomes studies in benign prostatic hyperplasia management, and site coordination for Washington University studies of viral infection and chronic placental inflammation in pregnancy.

Award volume grew from 6 in 2022 to 19 in 2024, with 18 awards in 2025 and 6 awards through mid-2026. Thirteen awards reach ultimate completion within the next twenty-four months, representing research continuity risk and recompete opportunity concentrated in NIDDK benign prostate research and multi-institute maternal-child health initiatives. The portfolio reflects a research-institution posture without procurement-contract competition, making Endeavor Health a potential collaborator or sub-recipient for federal contractors supporting NIH research infrastructure or clinical research site management, rather than a procurement competitor.